


Serial No. 09/926,712
Response to Office Action of July 30, 2003

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1 (currently amended): A serine protease inhibitor compound of formula (I)



where R₂ represents

(i) phenyl optionally being substituted in the 3 and/or 4 position by halo, nitro, thiol, haloalkoxy, hydrazido, alkylhydrazido, amino, ~~cyano~~, haloalkyl, alkylthio, alkenyl, alkynyl, acylamino, tri or difluoromethoxy, carboxy, acyloxy, MeSO₂- or R₁, and optionally substituted at the 6 position by amino, hydroxy, halo, alkyl, carboxy, alkoxycarbonyl, cyano, amido, aminoalkyl, alkoxy or alkylthio; or

(ii) naphth-2-yl optionally substituted at the 6 or 7 position by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R_{1j} and optionally substituted at the 3 position by amino, hydroxy, halo, alkyl, carboxy, cyano, amido, aminoalkyl, alkoxy or alkylthio;

~~(iii) isequinolin 7-yl, indol 5-yl, indol 6-yl, indazol 5-yl, indazol 6-yl, benzothiazol 6-yl or benzisoxazol 5-yl optionally substituted at the 3 position by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R_{1j};~~

~~(iv) benzimidazol 5-yl or benzothiazol 6-yl optionally substituted at the 2 position by amino;~~

Serial No. 09/926,712

Response to Office Action of July 30, 2003

~~(v) thien-2-yl or thien-3-yl optionally substituted at the 4 or 5 position by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R₁;~~

~~(vi) 3,4-methylenedioxyphenyl, 2,3-dihydroindol-6-yl, 3,3-dichloro-2-oxo-indol-6-yl or 1-methyl-3-aminoindazol-5-yl;~~

~~(vii) benzothiazol-2-yl, imidazo[1,2-a]pyrimidin-2-yl or tetrahydroimidazo[1,2-a]pyrimidin-2-yl;~~

~~(viii) pyrazol-2-yl optionally substituted at the 5 position by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R₁;~~

~~(ix) pyrid-2-yl optionally substituted at the 5 position by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R₁;~~

~~(x) pyrid-3-yl optionally substituted at the 6 position by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R₁;~~

~~(xi) benzofur-2-yl optionally substituted at the 3 position by amino, hydroxy, halo, alkyl, carboxy, cyano, amido, aminealkyl, alkoxy or alkylthio and at the 5 or 6 position by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R₁;~~

~~(xii) indol-2-yl optionally substituted on the indole nitrogen atom by alkyl and optionally substituted at the 5 or 6 position by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R₁;~~

~~(xiii) indol-6-yl substituted at the 5 position by amino, hydroxy, halo, alkyl, carboxy, alkoxycarbonyl, cyano, amido, aminealkyl, alkoxy or alkylthio and optionally substituted at the 3 position by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R₁; or~~

~~(xiv) benzo[b]thiophen-2-yl optionally substituted at the 3 position by amino, hydroxy, halo, alkyl, carboxy, cyano,~~

Serial No. 09/926,712
Response to Office Action of July 30, 2003

~~amido, aminoalkyl, alkoxy or alkylthio and at the 5 or 6 position by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R_{1j},~~

~~with the proviso that R₂ cannot be aminoisoquinolyl,~~

~~-X-X- is CONH each X independently is a C, N, O or S atom or a CO, CR_{1a}, C(R_{1a})₂ or NR_{1a} group, at least one X being C, CO, CR_{1a} or C(R_{1a})₂;~~

each R_{1a} independently represents hydrogen or hydroxyl, alkoxy, alkyl, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonyl, alkylaminocarbonyl, alkoxycarbonylamino, acyloxymethoxycarbonyl or alkylamino optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl;

R₁ is as defined for R_{1a}, provided that R₁ is not unsubstituted aminoalkyl;

L is CO, CH₂NH, CONR_{1d}(CH₂)_m, (CH₂)_mN(R_{1d})CO(CH₂)_m, (CH₂)_{m+2}, CO(CH₂)_m, (CH₂)_mCO, (CH₂)_mOC=O, (CH₂)_mO, CH=CH(CH₂)_m, SO₂, SO₂NR_{1d}, SO₂(CH₂)_m, (CH₂)_mSO₂ or (CH₂)_mSO₂NR_{1d} (where each m is independently 0 or 1 and R_{1d} is ~~hydrogen an organic linker group containing 1 to 5 backbone atoms selected from C, N, O and S, or a branched alkyl or cyclic group~~);


Y is a CH a ~~nitrogen atom or a CR_{1b} group~~;

Cy is a saturated or unsaturated, mono or poly cyclic, homo ~~or heterocyclic~~ group optionally substituted by groups R_{3a} or phenyl optionally substituted by R_{3a};


each R_{3a} independently is R_{1c}, amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, triazolyl, imidazolyl, tetrazolyl, hydrazido, alkyl imidazolyl, thiazolyl, alkyl thiazolyl, alkyl oxazolyl, oxazolyl, alkylsulphonamido, alkylaminosulphonyl, aminosulphonyl, haloalkoxy and haloalkyl;

Serial No. 09/926,712
Response to Office Action of July 30, 2003


Lp is a lipophilic organic group selected from



Serial No. 09/926,712
Response to Office Action of July 30, 2003




Serial No. 09/926,712
Response to Office Action of July 30, 2003




Serial No. 09/926,712

Response to Office Action of July 30, 2003



Serial No. 09/926,712

Response to Office Action of July 30, 2003




Serial No. 09/926,712

Response to Office Action of July 30, 2003.


wherein R_3 is as defined for R_{3a} m represents 0 or 1; R_4 represents hydrogen, $(CH_2)_wCOOH$ or $(CH_2)_wCONH_2$; w represents an integer from 0 to 4; and X represents CH or N D is a hydrogen bond donor group and n is 0;or $-L-Lp(D)_n$ is:

(i)

in which q is 1 or 2;

Q is a direct bond; and R_q is piperidin-4-yl which may bear a C_{1-3} alkyl substituent at the 1-position; or R_q is NR_aR_b in which each of R_a and R_b independently is hydrogen or C_{1-3} alkyl; or one of R_a and R_b is hydrogen or methyl and the other of R_a and R_b is $-CH_2-R_c$ or $-CH_2-R_d$ in which R_c is pyridyl or phenyl (which phenyl may bear a fluoro, chloro, methyl, $CONH_2$, SO_2NH_2 , methylaminosulphonyl, dimethylaminosulphonyl, methylsulphonylamino, methoxy or methylsulphonyl substituent) and in which R_d is isopropyl or cyclopentyl, or NR_aR_b is pyrrolidino, piperidino, morpholino, piperazino, or tetrahydro-1,4-diazepino in which a pyrrolidino or piperidino may be a 3,4-didehydro derivative and in which a pyrrolidino, piperidino, piperazino, or tetrahydro-1,4-diazepino may bear a methyl group at the 4-position;

(ii)



Serial No. 09/926,712

Response to Office Action of July 30, 2003

in which R_t is phenyl (which phenyl may bear a fluoro, chloro, C_{1-4} alkyl, methoxy or methylsulphonyl substituent); or
(iii)



in which Het is a divalent 5 membered heteroaromatic group containing 1, 2 or 3 heteroatoms selected from O, N and S and having the two ring atoms at which it is connected separated by one ring atom;

h is 0 or 1; and

R_h is phenyl which may bear one or more R_3 substituents;

and

R_{1b} , R_{1c} and R_{1j} are as defined for R_{1a} ,

or a physiologically tolerable salt thereof.

2 (canceled):

3 (canceled):

4 (canceled):

5 (canceled):

6 (currently amended): A compound as claimed in Claim 1, in which Y is a $CH-CR_{1b}$ group and has the conformation that would result from construction from a D- α -amino acid $NH_2-CH(Cy)-COOH$ $NH_2-CR_{1b}(Cy)-COOH$ where the NH_2 represents part of X-X.

7 (canceled):

Serial No. 09/926,712

Response to Office Action of July 30, 2003

8 (currently amended): A compound as claimed in Claim 17, in which Cy represents an optionally R_{3a} substituted phenyl, ~~pyridyl, thienyl, thiazolyl, naphthyl, piperidinyl~~ or cycloalkyl group.

9 (original): A compound as claimed in Claim 8, in which R_{3a} is selected from hydrogen, hydroxyl, methoxy, ethoxy, methyl, ethyl, methylaminomethyl, dimethylaminomethyl, hydroxymethyl, carboxy, methoxymethyl, methoxycarbonyl, ethoxycarbonyl, methylaminocarbonyl, dimethylamino-carbonyl, aminomethyl, CONH₂, CH₂CONH₂, acetyl amino, methoxycarbonylamino, ethoxycarbonylamino, t-butoxycarbonylamino, amino, fluoro, chloro, cyano, nitro, thiol, methylthio, methylsulphonyl, ethylsulphonyl, methylsulphenyl, methylsulphonylamido, ethylsulphonylamido, methylaminosulphonyl, ethylaminosulphonyl, aminosulphonyl, trifluoromethoxy and trifluoromethyl.

10 (currently amended): A compound as claimed in Claim 1, in which Cy is phenyl, 4-aminophenyl, 4-amidophenyl, 4-(N-methyl)amidophenyl, 4-(N,N-dimethyl)amidophenyl, 2-chlorophenyl, 2-methylphenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 4-hydroxyphenyl, 2-methoxyphenyl, 4-methoxyphenyl, 4-carboxyphenyl, 3-ethylsulphonylaminophenyl, ~~thien-2-yl, thien-3-yl, thiazol-4-yl, thiazol-5-yl, 2-methylthiazol-4-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, piperidin-4-yl, 1-methylpiperidin-4-yl, cyclohexyl or naphth-1-yl.~~

11 (canceled):

12 (currently amended): A compound as claimed in Claim 10~~11~~, in which L is CO, CONH, CH₂NHCO and/or CONHCH₂.

Serial No. 09/926,712
Response to Office Action of July 30, 2003


13. (canceled):

14. (canceled):

15 (canceled):

16 (previously presented) A compound as claimed in Claim 1,
in which in $-L-Lp(D)_n$ is:

(i)




in which q is 1 or 2;

Q is a direct bond; and R_q is piperidin-4-yl which may bear a C_{1-3} alkyl substituent at the 1-position; or R_q is NR_aR_b in which each of R_a and R_b independently is hydrogen or C_{1-3} alkyl; or one of R_a and R_b is hydrogen or methyl and the other of R_a and R_b is $-CH_2-R_c$ or $-CH_2-R_d$ in which R_c is pyridyl or phenyl (which phenyl may bear a fluoro, chloro, methyl, $CONH_2$, SO_2NH_2 , methylaminosulphonyl, dimethylaminosulphonyl, methylsulphonylamino, methoxy or methylsulphonyl substituent) and in which R_d is isopropyl or cyclopentyl, or NR_aR_b is pyrrolidino, piperidino, morpholino, piperazino, or tetrahydro-1,4-diazepino in which a pyrrolidino or piperidino may be a 3,4-didehydro derivative and in which a pyrrolidino, piperidino, piperazino, or tetrahydro-1,4-diazepino may bear a methyl group at the 4-position;

(ii)

Serial No. 09/926,712

Response to Office Action of July 30, 2003



in which R_t is phenyl (which phenyl may bear a fluoro, chloro, C_{1-4} alkyl, methoxy or methylsulphonyl substituent); or

(iii)



in which Het is a divalent 5 membered heteroaromatic group containing 1, 2 or 3 heteroatoms selected from O, N and S and having the two ring atoms at which it is connected separated by one ring atom;

h is 0 or 1; and

R_h is phenyl which may bear one or more R_3 substituents.

17 (previously presented): A compound as claimed in Claim 16, in which

(i) q is 2, and


R_q is piperidin-4-yl which may bear a (1-3C)alkyl substituent at the 1-position;

(iii) R_h is phenyl which may bear one or more R_3 substituents independently selected from, for an ortho or a para substituent: C_{1-5} alkyl, fluoro, chloro, difluoromethyl, trifluoromethyl, methoxy, dimethylamino, methylsulphonyl, and C_{1-2} acyl, and for a meta substituent: fluoro, chloro and methyl.

18 (previously presented): A compound as claimed in Claim 1, in which

$-L-Lp(D)_n$ is

Serial No. 09/926,712
Response to Office Action of July 30, 2003



in which R_h is phenyl which may bear an ortho and/or a para substituent independently selected from, for an ortho: methyl, fluoro, chloro, methylsulphonyl and acetyl, and for a para substituent: methyl, fluoro, chloro, methoxy and dimethylamino;




Z_1 is S, Z_2 is CH, n is 0; or

Z_1 is NH, Z_2 is N, n is 1.

19 (previously presented): A compound as claimed in Claim 1, in which R_3 is selected from hydrogen, hydroxyl, methoxy, ethoxy, methyl, ethyl, propyl, 2-propyl, butyl, 2-butyl, t-butyl, pentyl, 2-pentyl or 3-pentyl, isopropylaminomethyl, dimethylaminomethyl, diethylaminomethyl, dimethylaminoethyl, acetyl, hydroxymethyl, hydroxyethyl, carboxy, methoxymethyl, methoxycarbonyl, ethoxycarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, aminomethyl, aminocarbonyl, methylamino, dimethylamino, ethylamino, formylamino, acetylamino, amino, fluoro, chloro, cyano, nitro, thiol, methylthio, methylsulphonyl, ethylsulphonyl, isopropylsulphonyl, methylsulphenyl, 1,2,4-triazol-2-yl, 1,2,4-triazol-4-yl, 1,2,3-triazol-4-yl, 1,3-imidazol-1-yl or 1,3-imidazol-4-yl, tetrazol-1-yl, tetrazol-5-yl; methylsulphonamido, ethylsulphonamido, propylsulphonamido, methylaminosulphonyl, ethylaminosulphonyl, propylaminosulphonyl, aminosulphonyl, trifluoromethoxy, trifluoromethyl and trichloromethyl.


20 (previously presented): A compound as claimed in Claim 1, in which L_p is selected from

Serial No. 09/926,712
Response to Office Action of July 30, 2003



where R_8 represents H, OMe, SO_2Me , F, cyano, amido, amino, NO_2 , Cl or OH.

21 (previously presented): A compound as claimed in Claim 1, in which L_p represents



wherein X_2 is halo, hydrogen, amino, nitro or $CONH_2$.

22 (canceled):

23 (currently amended): A compound as claimed in Claim 1, in which R_2 represents:

(i) phenyl optionally being substituted in the 3 and/or 4 position by fluoro, chloro, bromo, iodo, nitro, difluoromethoxy, trifluoromethoxy, amino, ~~cyano~~, trifluoromethyl, methylthio, vinyl, carboxy, acetoxy, $MeSO_2-$, hydroxy, methoxy, ethoxy, methyl, methoxycarbonyl,

Serial No. 09/926,712
Response to Office Action of July 30, 2003

methylamino, ethylamino or amido, and optionally substituted at the 6 position by amino, hydroxy, fluoro, methoxycarbonyl, cyano or aminomethyl; or

(ii) naphth-2-yl optionally substituted at the 6, position by hydroxy and optionally substituted at the 3 position by amino or hydroxy;

~~(iii) isequinolin-7-yl, indol-5-yl, indol-6-yl, indazol-5-yl, indazol-6-yl, benzothiazol-6-yl or benzisoxazol-5-yl optionally substituted at the 3 position by chloro, bromo, amino, methyl or methoxy;~~

~~(iv) benzimidazol-5-yl or benzothiazol-6-yl optionally substituted at the 2 position by amino;~~

~~(v) thien-2-yl or thien-3-yl optionally substituted at the 4 or 5 position by methylthio, methyl or acetyl;~~

~~(vi) 3,4-methylenedioxyphenyl, 2,3-dihydroindol-6-yl, 3,3-dichloro-2-oxo-indol-6-yl or 1-methyl-3-aminoindazol-5-yl;~~

~~(vii) benzothiazol-2-yl, imidazo[1,2-a]pyrimidin-2-yl or tetrahydroimidazo[1,2-a]pyrimidin-2-yl;~~

~~(viii) pyrazol-2-yl substituted at the 5 position by methyl;~~

~~(ix) pyrid-2-yl optionally substituted at the 6 position by chloro;~~

~~(x) pyrid-3-yl optionally substituted at the 4 position by chloro;~~

~~(xi) benzofur-2-yl optionally substituted at the 3 position by chloro, methyl or methoxy, at the 5 or 6 position by methyl and at the 6 position by methoxy;~~

~~(xii) indol-2-yl optionally substituted on the indole nitrogen atom by methyl and optionally substituted at the 5 or 6 position by fluoro, chloro, bromo, methyl or methoxy;~~

~~(xiii) indol-6-yl substituted at the 5 position by chloro, fluoro or hydroxy and optionally substituted at the 3 position by chloro or methyl; or~~

Serial No. 09/926,712
Response to Office Action of July 30, 2003

~~(xiv) benzo[b]thiophen-2-yl optionally substituted at the 3 position by fluoro, chloro or methyl, and optionally substituted at the 5 or 6 position by fluoro, chloro, methyl, hydroxy, or methoxy.~~

24 (canceled):


25 (canceled):

26 (canceled):

27 (original): A pharmaceutical composition, which comprises a compound as claimed in Claim 1 together with at least one pharmaceutically acceptable carrier or excipient.

28 (previously presented): A compound as claimed in Claim 23, in which R_2 represents phenyl substituted in the 4 position by chloro, amino, vinyl, methylamino, methyl or methoxy, optionally at the 3 position with amino or hydroxy, and optionally at the 6 position with amino or hydroxy.

29 (currently amended): A serine protease inhibitor compound of formula (I)



where R_2 represents

(i) phenyl optionally being substituted in the 3 and/or 4 position by halo, nitro, thiol, haloalkoxy, hydrazido, alkylhydrazido, amino, cyano, haloalkyl, alkylthio, alkenyl, alkynyl, acylamino, tri- or difluoromethoxy, carboxy, acyloxy, MeSO_2 - or R_1 , and optionally substituted at the 6 position by

Serial No. 09/926,712

Response to Office Action of July 30, 2003

amino, hydroxy, halo, alkyl, carboxy, alkoxycarbonyl, cyano, amido, aminoalkyl, alkoxy or alkylthio; or

(ii) naphth-2-yl optionally substituted at the 6 or 7 position by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R_{1j} and optionally substituted at the 3 position by amino, hydroxy, halo, alkyl, carboxy, cyano, amido, aminoalkyl, alkoxy or alkylthio;

~~(iii) isequinolin-7-yl, indol-5-yl, indol-6-yl, indazol-5-yl, indazol-6-yl, benzothiazol-6-yl or benzisoxazol-5-yl optionally substituted at the 3 position by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R_{1j} ;~~

~~(iv) benzimidazol-5-yl or benzothiazol-6-yl optionally substituted at the 2 position by amino;~~

~~(v) thien-2-yl or thien-3-yl optionally substituted at the 4 or 5 position by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R_{1j} ;~~

~~(vi) 3,4-methylenedioxyphenyl, 2,3-dihydroindol-6-yl, 3,3-dichloro-2-oxo-indol-6-yl or 1-methyl-2-aminoindazol-5-yl;~~

~~(vii) benzothiazol-2-yl, imidazo[1,2-a]pyrimidin-2-yl or tetrahydroimidazo[1,2-a]pyrimidin-2-yl;~~

~~(viii) pyrazol-2-yl optionally substituted at the 5 position by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R_{1j} ;~~

~~(ix) pyrid-2-yl optionally substituted at the 5 position by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R_{1j} ;~~

~~(x) pyrid-3-yl optionally substituted at the 6 position by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R_{1j} ;~~


~~(xi) benzofur-2-yl optionally substituted at the 3 position by amino, hydroxy, halo, alkyl, carboxy, cyano, amido, aminoalkyl, alkoxy or alkylthio and at the 5 or 6~~

Serial No. 09/926,712

Response to Office Action of July 30, 2003

each R_{3a} independently is R_{1c} , amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, triazolyl, imidazolyl, tetrazolyl, hydrazido, alkyl imidazolyl, thiazolyl, alkyl thiazolyl, alkyl oxazolyl, oxazolyl, alkylsulphonamido, alkylaminosulphonyl, aminosulphonyl, haloalkoxy and haloalkyl.

L_p is group of formula:



in which:

r is 1 or 2;


one of X_a and X_b is N and the other is CH or N provided that when r is 1, X_a and X_b are not both N;

s , t and u are each 0 or 1;

L_a and L_b are each independently selected from a single bond, C=O , O and NR_{1e} , in which R_{1e} is hydrogen or (1-6C)alkyl;

G is (1-6C)alkanediyl; and

R_{10} is (1-6C)alkyl, (3-6C)cycloalkyl which is unsubstituted or substituted by (1-6C)alkyl, indanyl, pyridyl, tetrahydropyranyl, tetrahydrothiopyranyl, phenyl which is unsubstituted or substituted by one or two R_3 groups, pyrrolinyl, or a group of formula



in which v is 1, 2 or 3; one of X_c and X_d is N and the other is CH or N, provided that when v is 1, X_c and X_d are not both N; and R_{11} is hydrogen, (1-6C)alkyl or when X_d is CH, hydroxy(1-6C)alkyl; provided that when t is 0, the sum of s

Serial No. 09/926,712


Response to Office Action of July 30, 2003

and u is 1; when X_b is N, L_a is a bond or C=O; when X_c is N, L_b is a bond or C=O; when X_b and X_c are both N, t is 1; and when $(L_a)_s-(G)_t-(L_b)$ represents an alkyl group and X_b and X_c both represent N, the alkyl group contains at least two chain carbon atoms,

where L is CO or CH_2CO , when X_a is N, or L is CONH, $CONHCH_2$ or CH_2NHCO when X_a is CH;

but excluding compounds in which $-L-Lp(D)_n$ is:

(i)



in which q is 1 or 2;

(a) Q is -O- or -NH- and R_q is R_c ; or

(b) Q is methylene and R_q is NR_aR_b ;

each of R_a and R_b independently is hydrogen or C_{1-3} alkyl; or one of R_a and R_b is hydrogen or methyl and the other of R_a and R_b is $-CH_2-R_c$ or $-CH_2-R_d$ in which R_c is pyridyl or phenyl (which phenyl may bear a fluoro, chloro, methyl, $CONH_2$, SO_2NH_2 , methylaminosulphonyl, dimethylaminosulphonyl, methylsulphonylamino, methoxy or methylsulphonyl substituent) and in which R_d is isopropyl or cyclopentyl, or NR_aR_b is pyrrolidino, piperidino, morpholino, piperazino, or tetrahydro-1,4-diazepino in which a pyrrolidino or piperidino may be a 3,4-didehydro derivative and in which a pyrrolidino, piperidino, piperazino, or tetrahydro-1,4-diazepino may bear a methyl group at the 4-position;


(ii)

Serial No. 09/926,712
Response to Office Action of July 30, 2003



in which R_T is $-(CH_2)_c-R_C$, $-CH(R_e)R_f$, $-CH_2-CH(R_e)R_f$, or R_G in which c is 1 or 2 and R_C is defined as above; each of R_e and R_f independently is hydrogen or C_{1-3} alkyl; or $CH(R_e)R_f$ is cyclopentyl (which may bear a methyl, ethyl or hydroxymethyl substituent at the 3- or 4-position), cyclohexyl (which may bear a methyl, ethyl or hydroxymethyl substituent at the 3- or 4-position), tetrahydropyran-4-yl, tetrahydrothiopyran-4-yl, pyrrolidin-3-yl (which may bear a 1-methyl substituent), piperidin-4-yl (which may bear a 1-methyl substituent), or indan-2-yl; and R_G is 2-methylsulphonylphenyl which may bear a 4-fluoro substituent or R_G is 2,6-1,1-dioxobenzo[b]thiophen-7-yl;

(iii)




in which q is 1 or 2;

s is 0 or 1; and

R_S is $-(CH_2)_c-R_C$, $-CH(R_e)R_f$, or $-CH_2-CH(R_e)R_f$ each of which is defined as above; or

(iv)



Serial No. 09/926,712

Response to Office Action of July 30, 2003

in which R_t is piperidin-4-yl, piperidin-3-yl or pyrrolidin-3-yl, any of which may bear a C_{1-3} alkyl substituent at the 1-position;

D is a hydrogen bond donor group; and n is 0;

and

R_{1b} , R_{1c} and R_{1j} are as defined for R_{1a} ,
or a physiologically tolerable salt thereof.

30 (canceled):

31 (canceled):

32 (currently amended): A compound as claimed in Claim 29, in which Y is a CH CR_{1b} group and has the conformation that would result from construction from a D- α -amino acid $NH_2-CH(Cy)-COOH$ ~~$NH_2-CR_{1b}(Cy)-COOH$~~ where the NH_2 represents part of X-X.

33 (canceled):

34 (currently amended): A compound as claimed in Claim 33, in which Cy represents an optionally R_{3a} substituted phenyl, ~~pyridyl, thienyl, thiazolyl, naphthyl, piperidinyl~~ or cycloalkyl group.

35 (previously presented): A compound as claimed in Claim 34, in which R_{3a} is selected from hydrogen, hydroxyl, methoxy, ethoxy, methyl, ethyl, methylaminomethyl, dimethylaminomethyl, hydroxymethyl, carboxy, methoxymethyl, methoxycarbonyl, ethoxycarbonyl, methylaminocarbonyl, dimethylamino-carbonyl, aminomethyl, $CONH_2$, CH_2CONH_2 , acetylamino, methoxycarbonylamino, ethoxycarbonylamino, t-butoxycarbonylamino, amino, fluoro, chloro, cyano, nitro,

Serial No. 09/926,712
Response to Office Action of July 30, 2003

thiol, methylthio, methylsulphonyl, ethylsulphonyl, methylsulphenyl, methylsulphonylamido, ethylsulphonylamido, methylaminosulphonyl, ethylaminosulphonyl, aminosulphonyl, trifluoromethoxy and trifluoromethyl.

36 (currently amended): A compound as claimed in Claim 29, in which Cy is phenyl, 4-aminophenyl, 4-amidophenyl, 4-(N-methyl)amidophenyl, 4-(N,N-dimethyl)amidophenyl, 2-chlorophenyl, 2-methylphenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 4-hydroxyphenyl, 2-methoxyphenyl, 4-methoxyphenyl, 4-carboxyphenyl, 3-ethylsulphonylaminophenyl, ~~thien-2-yl, thien-3-yl, thiazol-4-yl, thiazol-5-yl, 2-methylthiazol-4-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, piperidin-4-yl, 1-methylpiperidin-4-yl~~, cyclohexyl or naphth-1-yl.

37 (previously presented): A compound as claimed in Claim 29, in which R₃ is selected from hydrogen, hydroxyl, methoxy, ethoxy, methyl, ethyl, isopropyl, 2-propyl, butyl, 2-butyl, t-butyl, pentyl, 2-pentyl or 3-pentyl, isopropylaminomethyl, dimethylaminomethyl, diethylaminomethyl, dimethylaminoethyl, acetyl, hydroxymethyl, hydroxyethyl, carboxy, methoxymethyl, methoxycarbonyl, ethoxycarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, aminomethyl, aminocarbonyl, methylamino, dimethylamino, ethylamino, formylamino, acetylamino, amino, fluoro, chloro, cyano, nitro, thiol, methylthio, methylsulphonyl, ethylsulphonyl, isopropylsulphonyl, methylsulphenyl, 1,2,4-triazol-2-yl, 1,2,4-triazol-4-yl, 1,2,5-triazol-4-yl, 1,3-imidazol-1-yl or 1,3-imidazol-4-yl, tetrazol-1-yl, tetrazol-5-yl; methylsulphonamido, ethylsulphonamido, propylsulphonamido, methylaminosulphonyl, ethylaminosulphonyl,

Serial No. 09/926,712

Response to Office Action of July 30, 2003

propylaminosulphonyl, aminosulphonyl, trifluoromethoxy, trifluoromethyl and trichloromethyl.

38 (currently amended): A compound as claimed in Claim 29, in which R₂ represents:

(i) phenyl optionally being substituted in the 3 and/or 4 position by fluoro, chloro, bromo, iodo, nitro, difluoromethoxy, trifluoromethoxy, amino, cyano, trifluoromethyl, methylthio, vinyl, carboxy, acetoxy, MeSO₂-, hydroxy, methoxy, ethoxy, methyl, methoxycarbonyl, methylamino, ethylamino or amido, and optionally substituted at the 6 position by amino, hydroxy, fluoro, methoxycarbonyl, cyano or aminomethyl; or

(ii) naphth-2-yl optionally substituted at the 6, position by hydroxy and optionally substituted at the 3 position by amino or hydroxy;

~~(iii) isequinolin-7-yl, indol-5-yl, indol-6-yl, indazol-5-yl, indazol-6-yl, benzothiazol-6-yl or benzisoxazol-5-yl optionally substituted at the 3 position by chloro, bromo, amino, methyl or methoxy;~~

~~(iv) benzimidazol-5-yl or benzothiazol-6-yl optionally substituted at the 2 position by amino;~~

~~(v) thien-2-yl or thien-3-yl optionally substituted at the 4 or 5 position by methylthio, methyl or acetyl;~~

~~(vi) 3,4-methylenedioxypheyl, 2,3-dihydroindol-6-yl, 3,3-dichloro-2-oxo-indol-6-yl or 1-methyl-3-aminoindazol-5-yl;~~

~~(vii) benzothiazol-2-yl, imidazo[1,2-a]pyrimidin-2-yl or tetrahydroimidazo[1,2-a]pyrimidin-2-yl;~~

~~(viii) pyrazol-2-yl substituted at the 5 position by methyl;~~

~~(ix) pyrid-2-yl optionally substituted at the 6 position by chloro;~~

Serial No. 09/926,712
Response to Office Action of July 30, 2003

~~(x) pyrid 3 yl optionally substituted at the 4 position by chloro,~~

~~(xi) benzofur 2 yl optionally substituted at the 3 position by chloro, methyl or methoxy, at the 5 or 6 position by methyl and at the 6 position by methoxy,~~

~~(xii) indol 2 yl optionally substituted on the indole nitrogen atom by methyl and optionally substituted at the 5 or 6 position by fluore, chloro, bromo, methyl or methoxy,~~

~~(xiii) indol 6 yl substituted at the 5 position by chloro, fluore or hydroxy and optionally substituted at the 3 position by chloro or methyl, or~~

~~(xiv) benzo[b]thiophen 2 yl optionally substituted at the 3 position by fluore, chloro or methyl, and optionally substituted at the 5 or 6 position by fluore, chloro, methyl, hydroxy, or methoxy.~~

39 (previously presented): A compound as claimed in Claim 38, in which R² is phenyl substituted in the 4 position by chloro, amino, vinyl, methylamino, methyl or methoxy, optionally at the 3 position with amino or hydroxy, and optionally at the 6 position with amino or hydroxy.

40 (canceled):

41 (previously presented): A pharmaceutical composition, which comprises a compound as claimed in Claim 29 together with at least one pharmaceutically acceptable carrier or excipient.

42 (new): A compound as claimed in Claim 1, which is selected from:

1-(3-Amino-4-chlorobenzoyl-D-phenylglyciny)-4-(4-fluoro-2-methylsulphonylphenyl)piperazine,

Serial No. 09/926,712
Response to Office Action of July 30, 2003

1-(3-Amino-4-chlorobenzoyl-D-phenylglyciny)-1'-methyl-4,4'-
bispiperidine;
1-(3-Amino-4-chlorobenzoyl-D-phenylglyciny)-4-(2-
methysulphonylphenyl)piperazine;
and physiologically tolerable salts thereof.

43 (new): A pharmaceutical composition, which comprises a
compound as claimed in claim 42 together with at least one
pharmaceutically acceptable carrier or excipient.